Literature DB >> 23216528

Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.

Thomas G Nührenberg1, Dietmar Trenk, Stefan Leggewie, Inga Ristau, Michael Amann, Christian Stratz, Willibald Hochholzer, Christian M Valina, Franz-Josef Neumann.   

Abstract

Current guidelines recommend prasugrel or ticagrelor for patients undergoing percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). Whereas available data support ticagrelor independent of pretreatment with clopidogrel, corresponding data for prasugrel are missing. Here, we investigated platelet reactivity after loading with prasugrel in clopidogrel-naïve vs. clopidogrel-pretreated patients. Forty-seven consecutive patients with STEMI referred for primary PCI were enrolled. Use of GPIIb/IIIa inhibitors and known contraindications to prasugrel served as exclusion criteria. A total of 31 patients were already treated with a loading dose of clopidogrel 600 mg by the emergency medical system before admission, while 16 patients were P2Y12 antagonist naïve. All patients received a loading dose of prasugrel 60 mg immediately before PCI. Adenosine diphosphate (ADP) induced platelet reactivity was determined by VerifyNow™ P2Y12 assay, by light transmission aggregometry (LTA) and by multiple electrode impedance aggregometry (MEIA; Multiplate™ analyser). No differences in platelet reactivity were observed at day 1 after PCI between the bolus-on-bolus treatment regimen and single prasugrel loading. Platelet reactivity was profoundly decreased to 10 [8-31] platelet reactivity unit (PRU; median [interquartile range]) in patients on clopidogrel + prasugrel vs. 9 [6-60] PRU in patients on prasugrel only (p = 0.916). Consistent results were obtained by LTA and MEIA. The proportion of patients reaching a MEIA associated with increased risk bleeding (<188 AU*min) was also similar between the two study groups. The level of platelet reactivity at day 1 after the 60 mg loading dose of prasugrel was independent of pretreatment with clopidogrel. Our results do not support withholding prasugrel in patients pretreated with clopidogrel who undergo PCI for STEMI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23216528     DOI: 10.3109/09537104.2012.736045

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  4 in total

Review 1.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Authors:  Fabiana Rollini; Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2015-08-18       Impact factor: 32.419

2.  Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.

Authors:  José Luis Ferreiro; José Carlos Sánchez-Salado; Montserrat Gracida; Ana Lucrecia Marcano; Gerard Roura; Albert Ariza; Josep Gómez-Lara; Victoria Lorente; Rafael Romaguera; Sílvia Homs; Guillermo Sánchez-Elvira; Luis Teruel; Kristian Rivera; Silvia Gabriela Sosa; Joan Antoni Gómez-Hospital; Dominick J Angiolillo; Angel Cequier
Journal:  J Cardiovasc Transl Res       Date:  2013-12-21       Impact factor: 4.132

3.  Introduction of new oral antiplatelet drugs in myocardial infarction hospital network: initial experience.

Authors:  Tomasz Rakowski; Artur Dziewierz; Zbigniew Siudak; Paweł Kleczyński; Jacek S Dubiel; Dariusz Dudek
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

4.  Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.

Authors:  Robert F Storey; Paul A Gurbel; Jurrien Ten Berg; Corine Bernaud; George D Dangas; Jean-Marie Frenoux; Diana A Gorog; Abdel Hmissi; Vijay Kunadian; Stefan K James; Jean-Francois Tanguay; Henry Tran; Dietmar Trenk; Mike Ufer; Pim Van der Harst; Arnoud W J Van't Hof; Dominick J Angiolillo
Journal:  Eur Heart J       Date:  2020-09-01       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.